Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...

FibroGen is focused on developing pamrevlumab, an innovative drug with potential for IPF treatment, which could capture a share of the multi-billion dollar IPF drug market. The PRAISE study showed ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease marked by gradual scarring, limiting lung function. The exact cause is unknown, but it combines genetic and environmental factors.

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

HealthDay News — Recommendations for idiopathic pulmonary fibrosis (IPF) treatment have been updated by an international group of respiratory societies. The updated clinical practice guideline was ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks An announcement from PureTech Health ...

Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...